Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
GENB compared with MCRB: revenue, margins and what each company keeps, and the suppliers and customers both name
GENB
Generate Biomedicines, Inc.
Change
Mkt cap
Revenue
Revenue
MCRB
Seres Therapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
GENB
Generate Biomedicines, Inc.
vs
MCRB
Seres Therapeutics, Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
Supply-chain overlap
Revenue flow
GENB: latest quarter is a loss; flow not drawable. MCRB: latest quarter not drawable.
Method
›
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
GENB, solid
MCRB, dashed
GENB
Generate Biomedicines, Inc.
Change
14.49
▼
−8.10%
· post 14.49
Mkt cap
$1.9B
Revenue
$6M
Q2 FY26
MCRB
Seres Therapeutics, Inc.
Change
1.76
▼
−9.72%
· post 1.76
Closed
Oct 30 '26
Mkt cap
$17.6M
Revenue
$736,000
Q2 FY26
vs
Compare
Closed
Oct 30 '26
GENB
Generate Biomedicines, Inc.
vs
MCRB
Seres Therapeutics, Inc.
14.49
▼
−8.10%
post 14.49
Price
1.76
▼
−9.72%
post 1.76
$1.9B
Mkt cap
$17.6M
Q2 FY26
$6M
Revenue
$736,000
Q2 FY26
Change
Change
GENB
14.49
▼
−8.10%
vs
MCRB
1.76
▼
−9.72%
Closed
Oct 30 '26
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only GENB
4
AMGN
Amgen
customer
NVS
Novartis Pharma
customer
—
The University of Texas MD Anderson Cancer Center
unlisted
supplier
—
Roswell Park Comprehensive Cancer Center
unlisted
supplier
Shared
0
No shared counterparties.
Only MCRB
11
—
Bacthera
unlisted
supplier
—
CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator)
unlisted
supplier
—
Crohn's and Colitis Foundation
unlisted
supplier
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
—
Columbia University
unlisted
supplier
7 more · MCRB chain
›